Skip to main content Skip to main navigation menu Skip to site footer

Case report: corticosteroid as an alternative therapy for Kawasaki disease


Background: Kawasaki disease is an acute febrile illness with systemic vasculitis and predominantly causes acquired heart disease. The etiology is still unknown, and there is no specific diagnostic test. The diagnosis was made using clinical criteria, laboratory and echocardiographic findings.  It is characterized by fever, bilateral non-exudative conjunctivitis, erythema of lips and oral mucosa, rash, cervical lymphadenopathy, edema and erythema of the hand and foot. The initial treatment for both complete and incomplete Kawasaki disease is a single high dose of intravenous immunoglobulin (IVIG) and aspirin. The place of corticosteroids in the initial therapy is still controversial.

Case Description: A 3-year-old boy presented with a 7-day history of high fever and not relieved by antipyretic, which was followed by a maculopapular rash on his trunk and extremities, vomiting, reduced appetite, red on her lips and eyes who aspirin, IVIG and corticosteroid treated as initial therapy. He showed clinical improvement and did not have cardiovascular complications.

Conclusion: We report a case of Kawasaki disease in a 3-year-old boy. This case highlighted that adding corticosteroids to IVIG and aspirin as initial therapy might improve outcomes in Kawasaki disease and could be selected as a treatment modality to treat Kawasaki disease.


  1. Division of High-Consequence Pathogens and Pathology. Kawasaki Disease [Internet]. Centers for Disease Control And Prevention (CDC). 2020 [cited January 21st, 2023]. Available from:
  2. Hasan K, Ilker D, Klc K, Tevfik K, Sema O, Bulent C. Kawasaki disease: a case report in extreme pediatrics. Infec Dis Clin Pr. 2006;14(5):333–4.
  3. Yun S, Park S. Associated symptoms of kawasaki disease. Korean Circ J. 2011;41(7):394–8.
  4. Saguil A, Fargo M, Grogan S. Diagnosis and management of kawasaki disease. Am Fam Physician. 2015;91(6):365–71.
  5. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. Vol. 135, Circulation. 2017. 927–999 p.
  6. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvemen. Pediatrics. 1979;63(2):175–9.
  7. Shinohara M, Sone K, Tomomasa T, Morikawa A. Corticosteroids in treating the acute phase of Kawasaki disease. J Pediatr. 1999;135:465–9.
  8. Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr. 2006;149(3):336–41.
  9. Green J, Wardle A, Tulloh R. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2022;5(5):1–31.
  10. Patel R, Schulman S. Kawasaki disease: a comprehensive revew of treatment options. J Clincal Pharm Ther. 2015;40(6):62–625.
  11. Setyawati NK, Sari AAIAN, Mahariski PA. Glucocorticoid-induced hyperglycemia (GIH) in pemphigus vulgaris patient at Bangli District General Hospital: A case report. Bali Dermatology Venereol J. 2019;2(2):28–33.
  12. Yu J. Use of Corticosteroids during acute phase of Kawasaki disease. World J Clin Pediatr. 2015;4(4):135–42.
  13. Newburger J, Sleeper L, McCrindle B, Minich L, Gersony W, Vetter V, et al. Randomized Trial of Pulsed Corticosteroid Therapy for Primary Treatment of Kawasaki Disease. N Engl J Med. 2007;356:663–75.

How to Cite

Izawati, E., Sandhi Parwata, & Maharani, P. T. (2023). Case report: corticosteroid as an alternative therapy for Kawasaki disease. Intisari Sains Medis, 14(2), 466–468.




Search Panel